Evidence map›Paper›PMID 30570428›Full record

ArticleHuman vaccines & immunotherapeutics2019

Response to article by Matthew Wasserman et al. (2018): "Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico".

Jorge A Gómez, Adriana Guzman Holst, Javier Nieto

Open access · hybridAbstract readComment
In one paragraph

Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jorge A Gómeza Health Outcomes Department , GSK , Victoria , Buenos Aires , Argentina.ORCID 0000-0001-5459-4973
Adriana Guzman Holstb Health Outcomes Department , GSK , Panama City , Panama.
Javier Nietoc Medical Affairs Department , GSK , Panama City , Panama.
City of Knowledge · PAPanama Canal Authority · PA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent article, Wasserman et al. estimated and forecasted the health and economic impact of switching from the 13-valent (PCV-13) to the 10-valent (PHiD-CV) pneumococcal conjugate vaccine in Mexico's national immunization program. In this response letter, we highlight various methodological inconsistencies and model input considerations that potentially bias the results and further recommendations made by the authors.

Indexed as

Pneumococcal InfectionsCost-Benefit AnalysisHumansMexicoPneumococcal VaccinesVaccines, ConjugatePneumococcal VaccinesVaccines, ConjugateCost effectivenessImmunization ProgramMexicoPneumococcal vaccines

Identifiers

PMID30570428
PMCPMC6988871
OpenAlexW2906420818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.